Category: Psychedelics

Read More

Compass cuts 30% of staff as late-stage psilocybin drug trials face new delays

Compass Pathways (NASDAQ: CMPS) plans to cut about 30% of its workforce and halt early-stage research programs as the firm focuses resources on completing late-stage trials of its lead COMP360 program. The London-based company announced the restructuring alongside third-quarter financial results that showed a widening net loss of $38.5 million …